| ||December 19, 2006|
Results of Toronto Hospital Study of Diabetic Mice Supports Sernova Corp's Cellular Therapy Technology
| ||Kelowna, B.C. -- Sernova Corp. today announced it is encouraged by the results of the study conducted with diabetic mice by Toronto researchers, and subsequently reported by several Canadian news outlets. The results appear to support Sernova's approach to treating diabetes in that Sertoli cells secrete, among other things, "substance P," the neuropeptide Toronto researchers injected into diabetic mice to reverse new onset diabetes. Sernova's approach to treating diabetes is to implant beneath the skin of diabetics, a small device containing insulin producing islets to reverse diabetes, and Sertoli cells to naturally protect the islets from the body's immune system.|
Sernova's chief scientist, Dr. David White was intrigued by the press reports, although he noted that these are preliminary studies and the approach does not address subjects that already have diabetes. He states, "It has been known for several years that Sertoli cells secrete tachykinins such as substance P. The recent news from Toronto would seem to confirm our belief that these secretions are an important component in generating the protective effect of Sertoli cells for islets. Substance P is a pain transmitter and induces vomiting. Therefore we maintain that the best approach is to replace the insulin producing cells that have been destroyed along with protective Sertoli cells, that we know secrete Substance P along with other important growth factors and immunoprotective compounds. We have also known for some time that Sertoli cells can prevent diabetes in the same strain of mice that the Toronto group used."
Sernova President Justin Leushner said, "The recent press coverage of this study confirms that a cure for diabetes is at the forefront of people's attention and that is why we are moving forward toward commercializing Sertolin our diabetes therapy, which is targeted for human diabetics."
Sernova's research is focused on compiling pre-clinical data to support an Investigational New Drug application to the United States Food and Drug Administration for their Sertolin Diabetes Therapy. The Company owns the exclusive rights to over 20 patents related to the therapeutic use of Sertoli cells.
Sernova Corp. is a Canadian based, health sciences company focused on commercializing medical technologies and currently working to cure insulin dependent diabetes. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. Over $100 billion per year is spent in the US on treating diabetes and its complications.
This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.
ON BEHALF OF THE BOARD
Justin Leushner, President
For further information contact:
TEL: (888) 318-7062
FAX: (250) 868-8493
THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.
You can view the Next News Releases item: Mon Jan 8, 2007, Award Winning Harvard Diabetes Specialist Appointed to Help Advance Sernova's Sertolin Diabetes Therapy to Clinical Trials
You can view the Previous News Releases item: Mon Dec 4, 2006, Leading Virologist Dr. Clive Patience Appointed to Help Guide the Development of Sernova's Proposed Diabetes Product
You can return to the main News Releases page, or press the Back button on your browser.